Form 8-K - Current report:
SEC Accession No. 0001437749-21-000377
Filing Date
2021-01-08
Accepted
2021-01-08 09:00:39
Documents
8
Period of Report
2021-01-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20210106_8k.htm 8-K 31799
2 EXHIBIT 1.1 SECURITIES PURCHASE AGREEMENT ex_220010.htm EX-1.1 263199
3 EXHIBIT 1.2 PLACEMENT AGENCY AGREEMENT ex_220013.htm EX-1.2 74275
4 EXHIBIT 4.1 FORM OF COMMON STOCK PURCHASE WARRANT ex_220012.htm EX-4.1 80892
5 EXHIBIT 5.1 OPINION OF GIBSON, DUNN & CRUTCHER LLP ex_220014.htm EX-5.1 8671
6 a01.jpg GRAPHIC 4417
7 a02.jpg GRAPHIC 6613
8 a03.jpg GRAPHIC 10380
  Complete submission text file 0001437749-21-000377.txt   489818
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 21515828
SIC: 2834 Pharmaceutical Preparations